<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0376-7892</journal-id>
<journal-title><![CDATA[Cirugía Plástica Ibero-Latinoamericana]]></journal-title>
<abbrev-journal-title><![CDATA[Cir. plást. iberolatinoam.]]></abbrev-journal-title>
<issn>0376-7892</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Cirugía Plástica, Reparadora y Estética (SECPRE)]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0376-78922020000400004</article-id>
<article-id pub-id-type="doi">10.4321/s0376-789220200004000004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Primer caso en Panamá de linfoma anaplásico de células grandes asociado a implantes mamarios (LACG-AIM)]]></article-title>
<article-title xml:lang="en"><![CDATA[First case in Panama of breast implant associated anaplastic large cell lymphoma (BIA-ALCL)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Picard-Ami Jr]]></surname>
<given-names><![CDATA[Luis A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Panamá  ]]></institution>
<addr-line><![CDATA[Panamá ]]></addr-line>
<country>Panamá</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<volume>46</volume>
<numero>3</numero>
<fpage>273</fpage>
<lpage>282</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S0376-78922020000400004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S0376-78922020000400004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S0376-78922020000400004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El linfoma anaplásico de células grandes asociado a implantes mamarios (LACG-AIM), es una enfermedad sumamente rara. Hasta noviembre 2019 solo se habían reportado 573 casos a nivel mundial. Sin embargo, ya en Panamá, un país pequeño con una población de 4.2 millones, se presentó el primer caso. Se trata de una paciente de 65 años, con seroma tardío en la mama derecha de 7 días de evolución e historia de implantes mamarios macrotexturizados durante los últimos 5 años. El análisis histopatológico de la pieza quirúrgica (capsulectomia completa) y del líquido de seroma confirmaron el diagnóstico de LACG-AIM. La enfermedad estaba limitada al liquido del seroma sin invasión de la cápsula periprotésica (T1AN0M0). El tratamiento consistió en retirada de los implantes, capsulectomía bilateral en bloque, y remplazo inmediato de los implantes. La evolución postoperatoria fue satisfactoria. En los controles clínicos y por imagen a los 2 años la paciente está libre de recurrencia local o enfermedad sistémica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Breast implant associated anaplastic large cell lymphoma (BIA.ALCL) is an extremely rare disease with only 573 cases reported worldwide up to November 2019. However, in Panama a small country with a population of 4.2 million, the first case already showed up. The patient is a 65-year-old female who presents with a one-week history of a delayed seroma on the right breast and a history of having macrotexture breast implants for the past 5 years. The diagnosis was confirmed with histopathological analysis of the complete capsule and the seroma fluid. The disease was confined to the seroma fluid without capsule invasion (T1AN0M0). Treatment consisted of bilateral implant removal with en bloc capsulectomies and immediate implant replacement. Her post op course has been uneventful with normal follow up. She remains free of local recurrence or distant disease up to 24 months post op.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Linfoma anaplásico células grandes asociado a implantes mamarios]]></kwd>
<kwd lng="es"><![CDATA[LACG-AIM]]></kwd>
<kwd lng="es"><![CDATA[Implantes mamarios texturizados]]></kwd>
<kwd lng="es"><![CDATA[Riesgos implantes mamarios]]></kwd>
<kwd lng="es"><![CDATA[Seroma tardío]]></kwd>
<kwd lng="en"><![CDATA[Breast implant associated anaplastic large cell lymphoma]]></kwd>
<kwd lng="en"><![CDATA[BIA-ALCL]]></kwd>
<kwd lng="en"><![CDATA[Textured breast implants]]></kwd>
<kwd lng="en"><![CDATA[Breast implants risk]]></kwd>
<kwd lng="en"><![CDATA[Late seroma]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keech Jr]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Creech]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>1997</year>
<volume>100</volume>
<page-range>554-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brody]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<source><![CDATA[Cells non-Hodgkin anaplastic lymphoma associated with one style of breast implants]]></source>
<year>2010</year>
<conf-name><![CDATA[ American Society of Plastic Surgeons Annual Conference]]></conf-name>
<conf-date>March 20-23</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Busum]]></surname>
<given-names><![CDATA[K van]]></given-names>
</name>
<name>
<surname><![CDATA[Schnyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mattke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anaplastic large cell lymphoma and breast implants: a systematic review]]></article-title>
<source><![CDATA[Plast Reconst Surg]]></source>
<year>2011</year>
<volume>127</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2141-50</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<source><![CDATA[FDA Update on the Safety of Silicone Gel-Filled Breast Implants]]></source>
<year>2011</year>
<publisher-name><![CDATA[Center for Devices and Radiological Health U.S. Food and Drug Administration]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<source><![CDATA[Anaplastic Large Cell Lymphoma (ALCL) in women with breast implants: preliminary FDA Findings and Analyses]]></source>
<year>2011</year>
<publisher-name><![CDATA[Center for Devices and Radiological Health U.S. Food and Drug Administration]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<source><![CDATA[FDA safety communication on BIA-ALCL]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<source><![CDATA[FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall certain breast implants and tissue expanders from market]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast implant-associated anaplastic large cell lymphoma]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Swerdlow]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
</person-group>
<source><![CDATA[WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues]]></source>
<year>2017</year>
<edition>4th</edition>
<page-range>421-2</page-range><publisher-loc><![CDATA[Lyon, France ]]></publisher-loc>
<publisher-name><![CDATA[International Agency for Research on Cancer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitzal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Kenner]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is breast implant associated anaplastic large cell lymphoma a hazard of breast implant surgery?]]></article-title>
<source><![CDATA[Open Biol]]></source>
<year>2019</year>
<volume>26</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres Rivero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos Gallardo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nambo Lucio]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vaquero Pérez]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primer caso en México y América Latina de linfoma anaplásico de células gigantes en paciente con implantes mamarios]]></article-title>
<source><![CDATA[Cir plást iberolatinoam]]></source>
<year>2016</year>
<volume>42</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>175-80</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Umaña Ordóñez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Recalde Losada]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio Verdú]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linfoma anaplásico de células grandes asociado a implantes mamarios. Cuatro casos diagnosticados en la provincia de Alicante, España]]></article-title>
<source><![CDATA[Cir plást iberolatinoam]]></source>
<year>2019</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>225-34</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vera García]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno Villalba]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Pascual]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primer caso en la Región de Murcia (España) de linfoma anaplásico de células grandes asociado a implantes mamarios]]></article-title>
<source><![CDATA[Cir plást iberolatinoam]]></source>
<year>2019</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>235-42</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández Sobrino]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cordones Guerrero]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Benítez Dupin]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Masa palpable como presentación atípica de linfoma anaplásico de células gigantes asociado a implantes mamarios]]></article-title>
<source><![CDATA[Cir plást iberolatinoam]]></source>
<year>2017</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>129-35</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clemens]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Horowitz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guías de consenso de NCCN (National Comprehensive Cancer Network) de diagnóstico y manejo del paciente con linfoma anaplásico de células grandes asociado a implantes mamarios]]></article-title>
<source><![CDATA[Aesth Surg J]]></source>
<year>2017</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>285-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clemens]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobsen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Horowitz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guías de Consenso del National Comprehensive Cancer Network NCCN para el diagnóstico y tratamiento del Linfoma de Células Grandes -Asociado a Implantes Mamarios]]></article-title>
<source><![CDATA[Aesth J]]></source>
<year>2019</year>
<volume>39</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>S3-S13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<source><![CDATA[Our SmoothSilk®/Silksurface®shell is classified in the smooth category according to ISO-14607:2018"Non-active surgical implants - Mammary implants - Particular requirements&#8221;, Annex H, Test for surface characteristics, which we had confirmed by independent testing conducted by Laboratoire National de Métrologie et d&#8217;Essais (LNE), a renowned third-party laboratory based in France]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
